Affordable Access

deepdyve-link
Publisher Website

Reduced mortality risk in malnourished hospitalized older adult patients with COPD treated with a specialized oral nutritional supplement: Sub-group analysis of the NOURISH study.

Authors
  • Deutz, Nicolaas E1
  • Ziegler, Thomas R2
  • Matheson, Eric M3
  • Matarese, Laura E4
  • Tappenden, Kelly A5
  • Baggs, Geraldine E6
  • Nelson, Jeffrey L6
  • Luo, Menghua6
  • Hegazi, Refaat7
  • Jonnalagadda, Satya S6
  • 1 Texas A&M University, College Station, TX, USA. Electronic address: [email protected]
  • 2 Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • 3 Medical University of South Carolina, Charleston, SC, USA.
  • 4 Brody School of Medicine at East Carolina University, Greenville, NC, USA.
  • 5 University of Illinois at Chicago, Chicago, IL, USA.
  • 6 Abbott Nutrition, Columbus, OH, USA.
  • 7 Abbott Nutrition, Columbus, OH, USA; Faculty of Medicine, Mansoura University, Mansoura, Egypt. , (Egypt)
Type
Published Article
Journal
Clinical nutrition (Edinburgh, Scotland)
Publication Date
Mar 01, 2021
Volume
40
Issue
3
Pages
1388–1395
Identifiers
DOI: 10.1016/j.clnu.2020.08.031
PMID: 32921503
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Hospitalized, malnourished older adults with chronic obstructive pulmonary disease (COPD) have an elevated risk of readmission and mortality. Post-hoc, sub-group analysis from the NOURISH study cohort examined the effect of a high-protein oral nutritional supplement (ONS) containing HMB (HP-HMB) in malnourished, hospitalized older adults with COPD and to identify predictors of outcomes. The NOURISH study (n = 652) was a multicenter, randomized, placebo-controlled, double-blind trial. The COPD subgroup (n = 214) included hospitalized, malnourished (based on Subjective Global Assessment), older adults (≥65 y), with admission diagnosis of COPD who received either standard-of-care plus HP-HMB (n = 109) or standard-of-care and a placebo supplement (n = 105) prescribed 2 servings/day from within 3 days of hospital admission (baseline) and up to 90 days after discharge. The primary study outcome was a composite endpoint of incidence of death or non-elective readmission up to 90-day post-discharge, while secondary endpoints included changes in hand-grip strength, body weight, and nutritional biomarkers over time. Categorical outcomes were analyzed using Cochran-Mantel-Haenszel tests, longitudinal data by repeated measures analysis of covariance; and changes from baseline by analysis of covariance. p-values ≤ 0.05 were considered statistically significant. Multivariate logistic regression was used to model predictors of the primary outcome and components. In patients with COPD, 30, 60, and 90-day hospital readmission rate did not differ, but in contrast, 30, 60, and 90-day mortality risk was approximately 71% lower with HP-HMB supplementation relative to placebo (1.83%, 2.75%, 2.75% vs. 6.67%, 9.52% and 10.48%, p = 0.0395, 0.0193, 0.0113, resp.). In patients with COPD, compared to placebo, intake of HP-HMB resulted in a significant increase in handgrip strength (+1.56 kg vs. -0.34 kg, p = 0.0413) from discharge to day 30; increased body weight from baseline to hospital discharge (0.66 kg vs. -0.01 kg, p < 0.05) and, improvements in blood nutritional biomarker concentrations. The multivariate logistic regression predictors of the death, readmission or composite endpoints in these COPD patients showed that participants who were severely malnourished (p = 0.0191) and had a Glasgow prognostic score (GPS) Score of 1 or 2 had statistically significant odds of readmission or death (p = 0.0227). Among malnourished, hospitalized patients with COPD, supplementation with HP-HMB was associated with a markedly decreased mortality risk, and improved handgrip strength, body weight, and nutritional biomarkers within a 90-day period after hospital discharge. This post-hoc, subgroup analysis highlights the importance of early identification of nutritional risk and administration of high-protein ONS in older, malnourished patients with COPD after hospital admission and continuing after hospital discharge. Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Report this publication

Statistics

Seen <100 times